翰森制药(03692):第四代EGFR-TKI HS-10504片用于非小细胞肺癌纳入突破性治疗药物

智通财经
May 21

智通财经APP讯,翰森制药(03692)发布公告,于2026年5月21日,本集团自研第四代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)HS-10504片获中国国家药品监督管理局(NMPA)批准纳入突破性治疗药物,拟定适应症为用于经EGFR-TKI治疗失败后伴EGFR C797S突变的局部晚期或转移性非小细胞肺癌(NSCLC)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10